ArticleJournal of ovarian research2026
Raddeanoside R7 inhibits proliferation and migration of ovarian cancer cells through P13K-AKT signaling.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOvarian cancer remains a therapeutic challenge due to high recurrence rates and chemoresistance, necessitating novel agents from natural sources. In our previous work, a triterpenoid saponin Raddeanoside R7 (R7) was isolated and characterized from Pulsatilla cernua (Thunb.) Bercht. ex J. Presl (P. cernua). Here, R7 was investigated for its anti-ovarian cancer potential.
methodsThe cytotoxic effects of R7 on Caov3 and OVCAR3 cells were evaluated using the CCK-8 assay. Cell migration was assessed via the Transwell migration assay. Flow cytometry was employed to analyze cell cycle distribution and apoptosis. The role of reactive oxygen species (ROS) production in R7’s inhibitory effects was investigated through fluorometric analysis using the DCFH-DA probe. The underlying mechanisms were further explored through integrated transcriptomics and network pharmacology, with core targets validated by molecular docking. The effect of R7 on underlying signaling pathway was examined by western blotting.
resultsR7 exhibited potent cytotoxicity against Caov3 and OVCAR3 cells, with half-maximal inhibitory concentrations (IC50) values of 7.27 µM and 8.25 µM, leading to significant inhibition of cell viability. The Transwell migration assay showed that R7 treatment reduced the number of migrated cells by over 60%. Flow cytometry analysis revealed that R7 induced S phase cell cycle arrest and promoted apoptosis, with early and late apoptosis rates increasing to a total of approximately 68% and 29.9% of Caov3 and OCVAR3 cells, respectively. Furthermore, ROS production was identified as a key mediator of these inhibitory effects. Integrated analysis identified CCND2 and HSPA8 as core targets, which was confirmed by molecular docking. Counterintuitively, activation of the PI3K-AKT pathway was found to potentially mediate the therapeutic effects of R7.
conclusionsR7 acts as a novel agent against ovarian cancer by inhibiting proliferation and migration, inducing S phase arrest and apoptosis, and elevating ROS levels. Its anti-tumor effects are potentially mediated through a context-dependent activation of the PI3K-AKT pathway, nominating R7 as a promising therapeutic candidate for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.